Skip to main content

Advertisement

Table 3 Conductance catheterization

From: Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction

  sham + vehicle sham + dapa sham + T-1095 MI + vehicle MI + dapa MI + T-1095
N 5 6 4 20 13 13
EDP (mmHg) 11 ± 2 12 ± 1 16 ± 2* 18 ± 1* 19 ± 1*‡ 26 ± 2*†
Pes (mmHg) 117 ± 11 127 ± 7 127 ± 15 107 ± 5 105 ± 5 95 ± 5*
HR (bpm) 296 ± 12 288 ± 12 299 ± 11 270 ± 7* 258 ± 6* 260 ± 9*
dP/dtmax (mmHg/s) 7031 ± 426 7471 ± 514 7815 ± 504 5443 ± 305* 5141 ± 249* 4201 ± 264*†‡
dP/dtmin (mmHg/s) − 7190 ± 631 − 7922 ± 637 − 8927 ± 906* − 4318 ± 260* − 4192 ± 224* − 3290 ± 246*†‡
EDPVR (mmHg/ml) 0.024 ± 0.004 0.025 ± 0.002 0.03 ± 0.01 0.06 ± 0.01 0.05 ± 0.01 0.10 ± 0.02*†‡
Tau (ms) 12.5 ± 0.6 12.6 ± 0.8 12.5 ± 0.7 17.5 ± 0.6* 18.0 ± 0.5* 23.2 ± 1.6*†‡
  1. EDP end-diastolic pressure, Pes end-systolic pressure, HR heart rate, EDPVR end-diastolic pressure volume relationship, ESPVR end-systolic pressure volume relationship
  2. * p < 0.05 vs. sham + vehicle group; † p < 0.05 vs. MI + vehicle group; ‡ p < 0.05 vs. MI + dapagliflozin group
Back to article page